$0.75 Earnings Per Share Expected for Medpace Holdings Inc (NASDAQ:MEDP) This Quarter

Equities analysts predict that Medpace Holdings Inc (NASDAQ:MEDP) will post earnings of $0.75 per share for the current quarter, Zacks reports. Five analysts have issued estimates for Medpace’s earnings, with the lowest EPS estimate coming in at $0.74 and the highest estimate coming in at $0.76. Medpace reported earnings of $0.76 per share during the same quarter last year, which indicates a negative year over year growth rate of 1.3%. The firm is scheduled to issue its next earnings report after the market closes on Monday, February 24th.

According to Zacks, analysts expect that Medpace will report full year earnings of $2.92 per share for the current year, with EPS estimates ranging from $2.91 to $2.93. For the next year, analysts anticipate that the company will post earnings of $3.32 per share, with EPS estimates ranging from $3.17 to $3.39. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Medpace.

MEDP has been the topic of several research analyst reports. BidaskClub raised shares of Medpace from a “buy” rating to a “strong-buy” rating in a report on Tuesday, December 24th. Zacks Investment Research cut shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Finally, SunTrust Banks cut shares of Medpace from a “buy” rating to a “hold” rating and upped their price target for the stock from $85.00 to $87.00 in a report on Monday, January 27th. Four equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $77.50.

In related news, CFO Jesse J. Geiger sold 14,400 shares of the stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $82.00, for a total value of $1,180,800.00. Following the transaction, the chief financial officer now owns 16,948 shares of the company’s stock, valued at $1,389,736. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 24.20% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vigilant Capital Management LLC purchased a new stake in Medpace during the fourth quarter valued at about $42,000. Ladenburg Thalmann Financial Services Inc. boosted its position in Medpace by 53.9% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 605 shares of the company’s stock valued at $40,000 after buying an additional 212 shares during the period. Exchange Traded Concepts LLC purchased a new stake in Medpace during the fourth quarter valued at about $80,000. Marshall Wace LLP purchased a new stake in Medpace during the first quarter valued at about $99,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Medpace by 32.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,848 shares of the company’s stock valued at $155,000 after buying an additional 452 shares during the period. 78.85% of the stock is currently owned by institutional investors and hedge funds.

Shares of Medpace stock traded up $0.08 during trading on Friday, hitting $97.86. The stock had a trading volume of 188,700 shares, compared to its average volume of 178,545. The firm has a market cap of $3.52 billion, a price-to-earnings ratio of 39.46, a P/E/G ratio of 2.27 and a beta of 1.50. Medpace has a 12 month low of $50.14 and a 12 month high of $98.70. The business’s 50-day moving average is $88.31 and its 200 day moving average is $81.13. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 0.07.

About Medpace

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Read More: Risk Tolerance

Get a free copy of the Zacks research report on Medpace (MEDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.